The Welsh Carson investment is expected to allow K2M to grow its business to meet the high demand for its product portfolio by expanding its worldwide sales force and accelerating the research and development of its next generation technologies.
K2M president and CEO Eric Major said that as a platform spine company, they have developed leading technologies to address the complex spine and the closure of this strategic transaction with Welsh Carson will enable to aggressively scale K2M in the global spine market.
“We are now primed to leverage the R&D efforts of the past six years to complete our tier one product portfolio. Our Serengeti Minimally Invasive Retractor System, which provides direct visibility through a flexible polymer retractor, is a prime example of a crossover technology we have developed at K2M to address both complex and degenerative pathologies,” Major said.
K2M’s complete portfolio of products include: spinal stabilization systems, minimally invasive systems, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement.
